je.st
news
Tag: therapeutics
Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
2015-08-05 07:56:18| drugdiscoveryonline Home Page
Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, recently announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and efficacy of HLD-200 – a next-generation formulation of methylphenidate – in children with Attention-Deficit/Hyperactivity Disorder (“ADHD”)
Tags: trial
patients
adhd
announces
Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock Options
2015-07-13 14:14:13| Agriculture - Topix.net
Antibe wishes to thank Dr. Bumby for his efforts in taking the Company public in 2013. Samira Sakhia has been named the Company's CFO on an interim basis replacing Dr. Bumby.
Tags: change
options
position
stock
Akcea Therapeutics obtains FDA Orphan Drug Designation for volanesorsen
2015-07-06 15:29:07| Biotech - Topix.net
Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. , announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to volanesorsen for the treatment of patients with Familial Chylomicronemia Syndrome . FCS is a rare genetic disease characterized by extremely high triglyceride levels and risk of pancreatitis.
Tags: drug
designation
fda
obtains
Bellerophon Therapeutics Announces Management and Board Additions
2015-07-02 00:40:09| Biotech - Topix.net
Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company, today announced the appointments of Amit Agrawal as Chief Operating Officer, effective July 8, 2015, and Naseem Amin, M.D. as an Independent Director of the Company, effective June 29, 2015. Mr. Agrawal joins Bellerophon from Amgen, Inc., where, since 2012, he served as Director of Strategy and Corporate Development.
Tags: board
management
additions
announces
Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping
2015-07-01 08:07:56| drugdiscoveryonline Home Page
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015
Tags: to
treatment
submission
fda
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] next »